Abstract
Background and Aims: The switching of vascular smooth muscle cell (VSMC) phenotype plays key roles in neointimal hyperplasia and its related arterial stiffness. Cluster of differentiation 147 (CD147), a member of the immunoglobulin super family that induces the expression of matrix metalloproteinase-9 (MMP-9) by dimerization, may play important roles in the switching of VSMC phenotype and may therefore be an effective target for the treatment of neointimal hyperplasia. Here, we investigated whether a novel drug SP-8356 ((1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one) targeting CD147 inhibitor could affects VSMC phenotype expression and inhibit neoitimal hyperplasia in atherosclerotic rat model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.